OJNeph  Vol.3 No.2 , June 2013
The Efficacy and Safety of Saxagliptin in Haemodialysis Patients
Abstract: Introduction: Good glycaemic control without causing excessive hypoglycaemia reduced the risk of macrovascular and microvascular complications in type 2 DM patients on regular haemodialysis (HD). The objectives of this study were to assess the efficacy and safety of add-on saxagliptin to insulin therapy in blood sugar control compared to insulin therapy alone in diabetic patients undergoing HD. Design and Methods: In this prospective open-labelled randomized controlled trial, HD patients with type 2 DM and on stable insulin therapy with HbA1c 7% - 13% were randomized to receive add-on saxagliptin 2.5 mg once daily to insulin therapy or insulin therapy only for 12 weeks. Results: 24 patients were randomized into each arm equally. Baseline and week-12 serum HbA1c, fructosamine, fasting blood glucose (FBS) and mean self monitoring blood glucose (SMBG) were comparable in the groups. Reduction of HbA1c and mean SMBG were significant in both groups. There was a significant drop in fructosamine levels (p = 0.004) and trend of lower FBS (p = 0.097) in add-on saxagliptin group but not in insulin alone group. The incidence of hypoglycaemia was the same in both groups. Conclusion: Add-on saxagliptin to insulin is comparable to insulin therapy alone in blood sugar control in regular HD patients and is safe and generally well tolerated. Add-on saxagliptin group may have more persistent and less fluctuation of glucose control compared to insulin only group.
Cite this paper: A. Gafor, A. Kadir, R. Cader, R. Mohd, K. Yen, R. Ghani, S. Shah and N. Kong, "The Efficacy and Safety of Saxagliptin in Haemodialysis Patients," Open Journal of Nephrology, Vol. 3 No. 2, 2013, pp. 83-88. doi: 10.4236/ojneph.2013.32014.

[1]   American Diabetes Association, “Standards of Medical Care in Diabetes—2010,” Diabetes Care, Vol. 33, Suppl. 1, 2010, pp. S11-S61. doi:10.2337/dc10-S011

[2]   Z. H. Israili, “Advances in the Treatment of Type 2 Diabetes Mellitus,” American Journal of Therapeutics, Vol. 18, No. 2, 2011, pp. 117-152. doi:10.1097/MJT.0b013e3181afbf51

[3]   M. J. Fowler, “Microvascular and Macrovascular Complications of Diabetes,” Clinical Diabetes, Vol. 26, No. 2, 2008, pp. 77-82.

[4]   D. M. Nathan, J. B. Buse, M. B. Davidson, et al., “American Diabetes Association; European Association for the Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, Vol. 32, No. 1, 2009, pp. 193-203. doi:10.2337/dc08-9025

[5]   L. Y. Ngo, et al., “18th Report of the Malaysian Dialysis and Transplant Registry All Renal Replacement Therapy in Malaysia,” The National Renal Registry, Kuala Lumpur, 2010, pp. 1-3.

[6]   K. Shrishrimal, P. Hart and F. Michota, “Managing Diabetes in Hemodialysis Patients: Observations and Recommendations,” Cleveland Clinic Journal of Medicine, Vol. 76, No. 11, 2009, pp. 649-655. doi:10.3949/ccjm.76a.09054

[7]   T. Oomichi, M. Emoto, T. Tabata, T. Morioka, Y. Tsujimoto, H. Tahara, T. Shoji and Y. Nishizawa, “Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis: A 7-Year Observational Study,” Diabetes Care, Vol. 29, No. 29, 2006, pp. 14961500. doi:10.2337/dc05-1887

[8]   M. E. Williams, E. Lacson Jr., M. Teng, N. Ofsthun and J. M. Lazarus, “Hemodialyzed Type I and Type II Diabetic Patients in the US: Characteristics, Glycemic Control, and Survival,” Kidney International, Vol. 70, No. 8, 2006, pp. 1503-1509. doi:10.1038/

[9]   KDOQI, “KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease,” American Journal of Kidney Diseases, Vol. 49, No. 2, 2007, pp. S12-S154. doi:10.1053/j.ajkd.2006.12.005

[10]   J. F. Yale, “Oral Antihyperglycemic Agents and Renal Disease: New Agents, New Concepts,” Journal of the American Society of Nephrology, Vol. 16, Suppl. 1, 2005, pp. S7-S10. doi:10.1681/ASN.2004110974

[11]   N. D. Lubowsky, R. Siegel and A. G. Pittas, “Management of Glycemia in Patients with Diabetes Mellitus and CKD,” American Journal of Kidney Diseases, Vol. 50, No. 5, 2007, pp. 865-879. doi:10.1053/j.ajkd.2007.08.012

[12]   K. Rave, T. Heise, A. Pfutzner, L. Heinemann and P. T. Sawicki, “Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients,” Diabetes Care, Vol. 24, No. 5, 2001, pp. 886-890. doi:10.2337/diacare.24.5.886

[13]   M. Stumvoll, “Glucose Production by the Human Kidney—Its Importance Has Been Underestimated,” Nephrology Dialysis Transplantation, Vol. 13, No. 12, 1998, pp. 2996-2999. doi:10.1093/ndt/13.12.2996

[14]   D. J. Drucker and M. A. Nauck, “GLP-1R Agonists (Incretin Mimetics) and DPP-4 Inhibitors (Incretin Enhancers) for the Treatment of Type 2 Diabetes,” Lancet, Vol. 368, No. 9548, 2006, pp. 1696-1705. doi:10.1016/S0140-6736(06)69705-5

[15]   A. A. Tahrani, M. K. Piya and A. H. Barnett, “Saxagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus,” Advances in Therapy, Vol. 26, No. 3, 2009, pp. 249-262. doi:10.1007/s12325-009-0014-9

[16]   D. J. Drucker, “The Role of Gut Hormones in Glucose Homeostasis,” Journal of Clinical Investigation, Vol. 117, No. 1, 2007, pp. 24-32. doi:10.1172/JCI30076

[17]   A. Barnett, “DPP-4 Inhibitors and Their Potential Role in the Management of Type 2 Diabetes,” International Journal of Clinical Practice, Vol. 60, No. 11, 2006, pp. 14541470. doi:10.1111/j.1742-1241.2006.01178.x

[18]   J. Rosenstock, C. Aguilar-Salinas and E. Klein, “CV181011 Study Investigators. Effect of Saxagliptin Monotherapy in Treatment-Naive Patients with Type 2 Diabetes,” Current Medical Research and Opinion, Vol. 25, No. 10, 2009, pp. 2401-2411. doi:10.1185/03007990903178735

[19]   B. J. Goldstein, M. N. Feinglos, J. K. Lunceford, J. Johnson and D. E. Williams-Herman, “Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with Type 2 Diabetes,” Diabetes Care, Vol. 30, No. 8, 2007, pp. 1979-1987. doi:10.2337/dc07-0627

[20]   American Diabetes Association Workgroup on Hypoglycemia, “Defining and Reporting Hypo-glycemia in Diabetes,” Diabetes Care, Vol. 28, No. 5, 2005, pp. 1245-1249. doi:10.2337/diacare.28.5.1245

[21]   Onglyza (Saxagliptin) Full Prescribing Information.

[22]   D. Boulton, A. Tang, C. Patel, L. Li, X. H. Xu, E. Frevert and D. Kornhauser, “Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin in Subjects with Renal Impairment,” Endocrine Abstracts, Vol. 20, 2009, p. 357.

[23]   M. S. Joy, W. T. Cefali, S. L. Hogan and P. H. Nachman, “Long-Term Glycemic Control Measurements in Diabetic Patients Receiving Hemodialysis,” American Journal of Kidney Diseases, Vol. 39, No. 2, 2002, pp. 297-307. doi:10.1053/ajkd.2002.30549

[24]   A. H. Barnett, B. Charbonnel, M. Donovan and D. Fleming, “Effect of Saxagliptin as Add-On Therapy in Patients with Poorly Controlled Type 2 Diabetes on Insulin Alone or Insulin Combined with Metformin,” Current Medical Research & Opinion, Vol. 28, No. 4, 2012, pp. 1-12. doi:10.1185/03007995.2012.665046

[25]   M. Nowicki, I. Rychlik, H. Haller, M. L. Warren, L. Suchower and I. G. Nilsson, “Saxagliptin Improves Glycemic Control and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus (T2DM) and Renal Impairment Compared with Placebo,” Diabetes, Obesity and Metabolism, Vol. 13, No. 6, 2011, pp. 523-532. doi:10.1111/j.1463-1326.2011.01382.x

[26]   E. Lamb, T. R. Venton, W. R. Cattell and A. Dawnay, “Serum Glycated Albumin and Fructosamine in Renal Dialysis Patients,” Nephron, Vol. 64, No. 1, 1993, pp. 8288. doi:10.1159/000187283

[27]   M. Inaba, S. Okuno, Y. Kumeda, et al., “Osaka CKD Expert Research Group. Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in Hemodialysis Patients with Diabetes: Effect of Anemia and Erythropoietin Injection,” Journal of the American Society of Nephrology, Vol. 18, No. 3, 2007, pp. 896-903. doi:10.1681/ASN.2006070772

[28]   C. Constanti, J. M. Simo, J. Joven and J. Camps, “Serum Fructosamine Concentration in Patients with Nephrotic Syndrome and with Cirrhosis of the Liver: The Influence of Hypoalbuminaemia and Hypergammaglobulinaemia,” Annals of Clinical Biochemistry, Vol. 29, No. 4, 1992, pp. 437-442.

[29]   H. C. Ford, W. C. Lim and M. J. Crooke, “Hemoglobin A1 and Serum Fructosamine Levels in Hyperthyroidism,” Clinica Chimica Acta, Vol. 166, No. 2-3, 1987, pp. 317321. doi:10.1016/0009-8981(87)90435-9

[30]   M. Jadzinsky, A. Pfützner and E. Paz-Pacheco, “CV181039 Investigators. Saxagliptin Given in Combination with Metformin as Initial Therapy Improves Glycemic Control in Patients with Type 2 Diabetes Compared with Either Monotherapy: A Randomized Controlled Trial,” Journal of Diabetes, Obesity and Metabolism, Vol. 11, No. 6, 2009, pp. 611-622. doi:10.1111/j.1463-1326.2009.01056.x

[31]   R. A. De Fronzo, M. Hissa, A. J. Garber, et al., “Saxagliptin 014 Study Group. The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients with Inadequately Controlled Type 2 Diabetes on Metformin Alone,” Diabetes Care, Vol. 32, No. 9, 2009, pp. 1649-1655. doi:10.2337/dc08-1984

[32]   A. R. Chacra, G. H. Tan, A. Apanovitch, S. Ravichandran, J. List and R. Chen, “Saxagliptin Added to a Submaximal Dose of Sulphonylurea Improves Glycaemic Control Compared with Uptitration of Sulphonylurea in Patients with Type 2 Diabetes: A Randomised Controlled Trial,” International Journal of Clinical Practice, Vol. 63, No. 9, 2009, pp. 1395-1406. doi:10.1111/j.1742-1241.2009.02143.x

[33]   P. Hollander, J. Li, E. Allen and R. Chen, “CV181-013 Investigators. Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone,” The Journal of Clinical Endocrinology & Metabolism, Vol. 94, No. 12, 2009, pp. 4810-4819. doi:10.1210/jc.2009-0550